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Insulin-degrading enzyme (IDE) is central to the turnover of
insulin and degrades amyloid  (A) in the mammalian brain.
Biochemical and genetic data support the notion that IDE may
play a role in late onsetAlzheimer disease (AD), and recent stud-
ies suggest an association between AD and diabetes mellitus
type 2.Herewe show that a natively folded recombinant IDEwas
capable of forming a stable complex with A that resisted dis-
sociation after treatment with strong denaturants. This interac-
tion was also observed with rat brain IDE and detected in an
SDS-soluble fraction from AD cortical tissue. A sequence
17–27, known to be crucial in amyloid assembly, was sufficient
to form a stable complex with IDE. Monomeric as opposed to
aggregatedAwas competent to associate irreversibly with IDE
following a very slow kinetics (t1⁄2  45 min). Partial denatur-
ation of IDE aswell as preincubationwith a 10-foldmolar excess
of insulin prevented complex formation, suggesting that the
irreversible interaction ofA takes placewith at least part of the
substrate binding site of the protease. Limited proteolysis
showed thatA remained bound to a25-kDaN-terminal frag-
ment of IDE in an SDS-resistant manner. Mass spectrometry
after in gel digestion of the IDEA complex showed that pep-
tides derived from the region that includes the catalytic site of
IDE were recovered with A. Taken together, these results are
suggestive of an unprecedented mechanism of conformation-
dependent substrate binding that may perturb A clearance,
insulin turnover, and promote AD pathogenesis.
Several neurodegenerative disorders are associated with the
progressive accumulation of amyloid  (A)3 in the brain,
including Alzheimer disease (AD) (reviewed in Ref. 1). A
accumulation has been attributed to several convergent mech-
anisms. These include a high rate of A production, a fast
kinetic of aggregation, and a defective clearance in the brain as
the result of impaired transport, protein-protein interactions,
or specific protease deficiencies (reviewed in Ref. 1). The first
two mechanisms may account for the accelerated A deposi-
tion in rare hereditary disorders caused by mutations in the
amyloid precursor protein (APP) or presenilin genes, whereas
the latter may be relevant in the complex pathogenesis of the
more frequent sporadic AD. It is now accepted that self-assem-
bly of A follows a nucleation kinetic (2). In this process, nucle-
ation takes place above the critical concentration of the peptide,
and, therefore, the transient and steady levels ofmonomericA
in the brain and the mechanisms that regulate them acquire a
major importance. Although the input of A depends largely
on the rate of proteolytic release from APP, its clearance
depends on diffusion, transport, and degradation. Neprilysin,
insulin-degrading enzyme (IDE), and endothelin-converting
enzyme are thought to be A proteases of major physiological
relevance, as shown by gene knock-out and overexpression ani-
mal models (3–7). IDE is a highly conserved and ubiquitous
Zn2 metalloendopeptidase that belongs to the M16 family
defined by an “inverted” canonical sequence in the active site
(HXXEH instead ofHEXXH), as comparedwith othermembers
of the clan (8). Although the precise physiological role of IDE is
unknown, its deficiency after gene targeting in mice leads to a
biochemical phenotype that includes hyperinsulinemia, glu-
cose intolerance, elevated levels of soluble A in the brain, and
a substantial increase in the 50-residue C-terminal intracel-
lular domain of APP (4, 5). These findings, together with pre-
ceding work on cell cultures, support that IDE participates in
the degradation of these peptides in vivo, regulating their phys-
iological levels (9, 10). In addition, IDE has been shown to
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Supplemental Material can be found at: 
degrade a number of peptides of diverse sequence and func-
tions, including several with the potential to form amyloid in
vivo or in vitro. Apart from insulin, IDE can degrade glucagon,
atrial natriuretic peptide, calcitonin, amylin, A, including all
its genetic variants, amyloid Bri, and amyloid Dan (reviewed in
Refs. 11–13). It has been long proposed that IDE specificity is
dictated in part by substrate backbone conformation, a predic-
tion that has been confirmed by recent crystallographic data
(11, 14). A growing number of studies suggest a possible genetic
association of IDE polymorphisms with sporadic late-onset AD
(reviewed in Ref. 15). In addition, recent work supports the
association between diabetesmellitus type 2, hyperinsulinemia,
and the risk for developing AD, placing IDE as a protein that
may link several biochemical features of these diseases
(reviewed inRefs. 16 and 17). The expression and activity of IDE
have been reported to be reduced in the hippocampus and cor-
tex in sporadic AD and in cortical microvessels affected with
amyloid angiopathy (18–20). It has been proposed that part of the
loss of IDE activity may be accounted for by lower IDE mRNA
levels or post-translational modifications such as oxidative dam-
age (21, 22). In this studywereport theunexpected finding thatA
forms ahighly stable complex that comprises part of the active site
of IDE, suggesting a novel interaction between IDE and A with
potential implications in AD pathogenesis.
MATERIALS AND METHODS
Peptides and Antibodies—A1–28, bovine insulin, bovine
ubiquitin, and human growth hormone releasing factor 1–40
(GRF) were from Sigma; A1–40 and A1–42 were from
Bachem; A17–40, ACys16–28, and ACys17–27 were syn-
thesized at the W. M. Keck facility at Yale University. [125I]In-
sulin (specific activity, 270 Ci/g) was a gift of Edgardo
Poskus, University of Buenos Aires. Synthetic A1–40E22Q
was kindly provided by Dr. Jorge Ghiso (New York University).
Human cystatin C (CysC) was from Merck Biosciences. Anti-
bodies against A 6E10 (positions 4–13) and 4G8 (positions
17–24) were from Signet Labs, Dedham,MA. Rabbit polyclonal
anti-ubiquitin was from Sigma. The rabbit antisera S40 and
S42, specific for A40 and A42, respectively, were gifts of Dr.
Mikio Shoji (Okayama University, Japan). Rabbit antiserum
BC2 was generated against a glutathione S-transferase fusion
protein comprising residues 97–273 of rat IDE, as previously
described (12). Monoclonal antibody 3A2 against rat IDE was
produced and purified as reported previously (20). Rabbit anti-
CysC was raised with purified human CysC from urine follow-
ing standard protocols and characterized by ELISA and West-
ern blot. Human endogenous A1–40 with the E22Q
substitutionwas purified and characterized from the leptomen-
inges of a case of hereditary cerebral hemorrhage with amyloi-
dosis, Dutch type (HCHWA-D), as previously reported (23).
Fluorescein Labeling of A—ACys16–28 and ACys17–27
(1.5 mg/ml) were incubated with a 10-fold molar excess of
Tris(2-carboxyethyl)phosphineHCl in 50mMphosphate, pH 7,
for 1 h at room temperature followed by the addition of 60l of
2.5 mg of fluoresceinmaleimide (Molecular Probes) in DMSO.
The reaction was incubated overnight at 4 °C in the dark and
stopped by the addition of -mercaptoethanol to a final con-
centration of 50 mM. Peptides were purified by reversed-phase
chromatography with a C18 column (Beckman Ultrasphere
ODS), and the eluate was monitored at 215 nm. HPLC peaks
were analyzed by mass spectrometry as described below to
assess the incorporation of fluorescein. The peaks containing
single peptideswithm/z of 1983.3 and 1726.5, corresponding to
fluorescein-labeled ACys16–28 and ACys17–27 (FAs) at a
1:1 stoichiometry, respectively, were identified. The concentra-
tions of these derivativeswere determined by absorbance at 492
nm in 0.1 M Tris HCl, pH 9 (extinction coefficient 83,000 cm1
M1)with aBeckman-Coulter spectrophotometer and stored in
the HPLC elution solvent at 80 °C for binding experiments.
Recombinant IDE Purification—Recombinant rat IDE
42–1019 (rIDE) was subcloned from pECE-IDE into pET-
30a() (Novagen, Darmstadt, Germany), expressed in Esche-
richia coli BL21 and purified using a Hi-Trap Ni2 chelating
column as described (20). Further purification was obtained by
size exclusion chromatography on a Superdex 200 column
(Amersham Biosciences). On-line laser light scattering data
were collected with a PD2010 detector. The relation between a
90° static light scattering signal and UV absorbance or refrac-
tive index signal was used to calculate molecular mass and
hydrodynamic diameter with the Discovery 32 software (Preci-
sion Detectors, Bellingham, MA). The purity, folding parame-
ters, and activity of rIDE are shown in supplemental Fig. S1.
Protein concentration was determined by absorbance at 280
nm (extinction coefficient, 115,810 cm1 M1) and by a bicin-
choninic acid assay (Pierce) and expressed as monomeric rIDE.
Spectroscopic Studies—CD measurements were carried out
on a Jasco J-810 spectropolarimeter. Far-UV spectra were col-
lected using a Peltier temperature-controlled sample holder at
25 °C in a 0.2-cm path length cell, with rIDE concentration of
0.8M in 50mM sodiumphosphate, pH 7.2. Fluorescence emis-
sion spectra were recorded on an Aminco-Bowman spectroflu-
orometer with an excitation wavelength of 295 nm in the same
buffer and rIDE concentration as above. Denaturation of rIDE
induced by urea was assessed by the loss ofmolar ellipticity at 222
nmand changes in the center of spectralmass of Trp fluorescence
at the indicated urea concentrations in the same buffer as above.
rIDEA Complex Formation and Treatments—Peptides and
rIDEwere incubated at the indicated concentrations andmolar
ratios in 0.1 M phosphate, pH 7.2, for 3 h at 37 °C with constant
agitation at 350 rpm in a Thermomixer Comfort block (Eppen-
dorf). The reaction was stopped by the addition of an equal
volume of 0.25 M Tris-HCl, pH 6.8, 40% glycerol, 4% SDS con-
taining 0.1 M dithiothreitol (sample buffer, SB). To assess the
effect of urea and formic acid, the reaction volume was dried
under vacuum followed by the addition of 8 M urea in 0.1 M
phosphate, pH 7.2, or 70% formic acid, respectively and incu-
bated for 2 h at 37 °C. Acid-treated samples were dried under a
stream ofN2 before the addition of electrophoresis SB. For gua-
nidine-HCl treatment, to a 20-l reaction of rIDE andA1–28,
180 l of 7.5 M guanidine in HCl (10 mM) or 180 l of milli-Q
water were added, and the samples were incubated for 1 addi-
tional hour at 37 °C. After bringing the final volume to 1.8 ml
with water, proteins were precipitated with trichloroacetic
acid, centrifuged at 15,000 g at 4 °C for 30 min, and carefully
washed with ice-chilled acetone to remove the excess of guani-
dine. This last step was repeated three times. The pellet was
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dried under vacuum, and then resuspended with SB for SDS-
PAGE and Western blot. A1–40E22Q was incubated at 250
M in PBS for 3 weeks or applied freshly after disaggregation
(see below) for incubation with rIDE. For the time-course
experiments, A1–28 was pretreated with 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP) as described (24) and incubated
at 100:1 molar ratio (A:IDE) in 20 l of 0.1 M sodium phos-
phate, pH 7.2, in the presence or absence of 5mM EDTA for the
indicated times at 37 °C. The reaction was stopped by boiling in
20 l of SB, and samples were stored at 80 °C until the electro-
phoresis was performed. Data from two experiments in duplicate
were fit to a single exponential equation and analyzedwithGraph-
Pad Prism 4 software. Competition experiments were carried out
by incubating increasing concentrationsof insulinorGRFwith2.5
MFA16–28 and 50nM rIDE for the indicated periods of time at
37 °C in 0.1 M phosphate, pH 7.2, containing 5mM EDTA.
Dynamic Light Scattering and Aggregation Assay—A1–28
was pre-treated with HFIP to disaggregate oligomers, dried
under nitrogen, dissolved to a final concentration of 100 M in
0.1 M phosphate, pH 7.2, and filtered through a 0.22-mmem-
brane. This sample was incubated al 37 °C for up to 72 h, and
particle size was assessed at the indicated times by dynamic
light scattering using the excitation laser at 633 nm and a detec-
tor angle: of 173° with a Zetasizer Nano-S (Malvern Instru-
ments). After the indicated incubation times, data were
expressed as particle relative abundance versus particle hydro-
dynamic diameter. To study the aggregation kinetic of
FACys16–28, the peptide stock was lyophilized, dissolved at
the indicated concentrations in 0.1 M phosphate, pH 7.2, and
layered upon an equal volume of 20% sucrose in the same
buffer. After incubation for the indicated times at 37 °C with
continuous agitation at 350 rpm, samples were centrifuged at
10,000  g for 30 min. Aliquots from the supernatant were care-
fully removed anddissolved in 50mMTris-HCl, pH9, and absorb-
ancewasmeasured at 492 nm.Data from two independent exper-
iments in duplicate were expressed as percentage of soluble
peptide, taking the dead time of the experiment as 100%.
IDEASCx Formation with Endogenous IDE—Brains were
obtained from adult Sprague-Dawley rats following protocols
approved by the Fundación Instituto Leloir Ethical Committee.
Tissue was homogenized in Tris-HCl-buffered saline, pH 8
(TBS), containing a mixture of protease inhibitors (Sigma) and
centrifuged at 100,000  g for 1 h at 4 °C. One milligram of
proteins from the supernatant was immunoprecipitated with
monoclonal antibody 3A2 coupled to CNBr-activated Sepha-
rose overnight at 4 °C. After washing with 0.4 M NaCl, 0.1 M
Tris-HCl, pH8, the pelletswere incubatedwith 2g ofA1–40
in 40 l of 0.1 M phosphate, pH 8, for 3 h at 37 °C and centri-
fuged at 3000 rpm for 3 min, and the beads were boiled in 30 l
of SB. Proteins were separated on 7.5% SDS-PAGE and
IDEASCx detected by Western blot with antibody S40 as
described below. Negative controls included the immunopre-
cipitation with an unrelated mouse IgG, 3A2-Sepharose beads
with buffer alone, and rat brain proteins with protein G alone.
IDEASCx Detection in Rat Brain—The pellet obtained
from the rat brain homogenate as described above was homog-
enized in 10 volumes of TBS containing protease inhibitors, 1%
Triton X-100, and 0.1% SDS and centrifuged at 100,000  g for
1 h at 4 °C. Onemilligram of proteins from the supernatant was
immunoprecipitated as indicated before with 3A2 or unrelated
mouse IgG in the same buffer without SDS. After washing, pro-
teins were separated on SDS-PAGE and subjected to Western
blot with anti-A S40 and S42.
IDEASCxDetection inADBrain—Brain samples of definite
AD cases were obtained from participants enrolled in the Brain
Donation Program of Sun Health Research Institute (Sun City,
AZ). Approximately 300 mg of frontal cortex from each case
was dissected on ice, pooled (n  5), homogenized, and centri-
fuged as described above. The pellet was homogenized in TBS
containing protease inhibitors and 2% SDS and centrifuged at
100,000  g for 1 h at 4 °C. One milligram of proteins from the
water and SDS-soluble fractions were used for immunoprecipi-
tation with anti-IDE 3A2 coupled to Sepharose in TBS-0.2%
SDS. Proteins were resolved on SDS-PAGE and detected by
Western blot using anti-A S42, S40, and BC2 (see below). For
urea treatment, the beads pellet was resuspended in 2 vol. of SB
containing 9 M urea. Negative controls included immunopre-
cipitation of brain proteins with an unrelated mouse IgG cou-
pled to Sepharose and 3A2 beads with buffer alone.
High Performance Liquid Chromatography—The separation
of rIDEA complexes by HPLC was performed with a C4
Brownlee BU-300 (30 2.1mm) columnusing a linear gradient
from 0 to 100% acetonitrile (ACN) in 0.1% trifluoroacetic acid
at 0.2ml/minmonitored at 214 nm.The peakswere analyzed by
ELISA as described below. For the purification of FA peptides,
a C18 Beckman Ultrasphere (250  4.6 mm) was used, with a
linear gradient from 0 to 100% acetonitrile in 0.1% trifluoroace-
tic acid at 1ml/min. Peakswere detected at 214 nm, collected, and
concentrated with a SpeedVac, and peptides were quantitated as
described above and analyzed by mass spectrometry (see below).
After in gel endoproteinase LysC (endo-LysC) digestion of
rIDEA complex, peptides were separated using a linear gradient
from 0 to 100%ACN in 0.1% trifluoroacetic acid in 75min.
Enzyme-linked Immunoadsorbent Assay—Aliquots of 20 l
from all the peaks obtained from HPLC were mixed with 80 l
of 0.1% trifluoroacetic acid, 50% ACN, placed on polystyrene
microtiter plates (Nunc), and incubated at 37 °C until evapora-
tion (typically overnight). After blocking with 3% bovine serum
albumin in PBS for 2 h at 37 °C, wells were incubated with
antibodies 6E10, 4G8, S40, or BC2 overnight at 4 °C in 0.3%
bovine serum albumin in PBS followed by horseradish peroxi-
dase-conjugated anti-mouse or rabbit IgG (Amersham Bio-
sciences) for 2 h at room temperature in the same buffer. Reac-
tivity was developed with ortho-phenylenediamine and H2O2
for 10min, stoppedwith 1 N SO4H2, and the optical density was
measured at 490 nm with a microtiter plate reader 550 (Bio-
Rad, Hercules, CA). After subtraction of background levels
(wells without peptide), optical density values were plotted and
analyzed with GraphPad Prism version 4. To better reflect the
total immunoreactive proteins obtained from eachHPLC peak,
results were expressed as the product of optical density at 490
nm and peak volume, in arbitrary units.
SDS-PAGE, Western Blot, and Fluorescence Detection—Pro-
teins were run on 7.5 or 12.5%Tris-Tricine gels and transferred
to polyvinylidene difluoride (PVDF) membranes. In some
experiments, gels were cut horizontally at the level of the
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67-kDa molecular mass marker. The lower half was stained
with Coomassie Blue, and the upper half was transferred at 400
mA for 3 h to detect rIDE and rIDEA complexes. Protein
complexes formed between rIDE and unlabeled A peptide
were detected and quantified by Western blot. Membranes
were blocked with 5% low fat milk in PBS for 2 h at 37 °C and
with the indicated primary antibodies overnight at 4 °C. Immu-
noreactivity was detectedwith anti-rabbit or anti-mouse horse-
radish peroxidase-labeled IgG and enhanced chemilumines-
cence using ECL Plus reagents (Amersham Biosciences).
Western blots were scanned with a STORM 860 fluorometer
and analyzed with ImageQuaNT 5.1 software (Molecular
Dynamics). For fluorescence assessment, PVDF membranes
were equilibrated in PBS for 45 min, air-dried, and scanned in
blue fluorescence mode with the photomultiplier set at 975 V.
The intensity of the fluorescent signal as a function of peptide
mass was determined by dot-blot on PVDF membranes with
FAs. The amount of total rIDE was estimated by Coomassie
Blue staining of the same membranes used for fluorescence
detection. For N-terminal sequence, proteins were digested with
trypsinat 1:200 for15minat roomtemperature, subjected toSDS-
PAGE, and transferred to PVDF. After staining with 0.1% Coo-
massie Blue the band of interest was cut and subjected to Edman
degradation with a 477A sequencer (Applied Biosystems).
In-gel Digestion—After SDS-PAGE and Coomassie Blue
staining, the band of 120 kDa containing the rIDEA (FA17–
27) complex was cut, and the gel slice was incubated in 100 mM
Tris-HCl, pH 8.8 (digestion buffer), with 45 mM dithiothreitol
for 30 min at 60 °C. The tube was cooled at room temperature,
and 100 mM iodoacetamide was added, followed by incubation
for 30 min in the dark at room temperature. The gel was then
washed in 50% ACN with shaking for 1 h, cut in 1-mm pieces,
and transferred to a small tube. The gel pieces were shrunk in
ACN, dried in a rotator evaporator, and re-swollenwith 10l of
digestion buffer containing 0.1 mg/ml endo-LysC (Roche
Applied Science). The samplewas incubated overnight at 37 °C,
and digestion products were extracted twice from the gel with
60% ACN/0.1% trifluoroacetic acid for 20 min. Combined
extractionswere loaded into aC18HPLC column and separated
as described above. Seventy-six 1-min fractions were collected,
and volumes were reduced to 50 l with a rotator evaporator
andapplied to aPVDFmembrane inPBS fordot-blot fluorescence
detection and 4G8 immunoreactivity as described before. Those
fractions in which the presence of FA17–27 was detected were
further analyzed by mass spectrometry. Negative controls
included digestion of rIDE alone and a blank piece of gel.
Mass Spectrometry Analysis—FA peptides and products of
endo-LysC of rIDE in the presence or absence of A were ana-
lyzed by matrix-assisted laser desorption/ionization time-of-
flight (MALDI-TOF). To produce the dried droplets, a satu-
rated solution of -cyano-4-hydroxycinnamic acid (Fluka) was
prepared using 0.1% trifluoroacetic acid-30% ACN at room
temperature. Equal volumes from this solution and the sample
were mixed, and 1 l was placed on the probe, allowed to dry,
and analyzed on linear mode in an Omniflex spectrometer
(Bruker Daltonics). Calibration was performedwith the follow-
ing peptides for which averagem/z values are shown in paren-
theses: bradykinin 1–7 (757.86), angiotensin I (1297.49), renin
substrate (1760.04), microperoxidase (1862.95), insulin B chain
(3496.92), and insulin (5734.54). Peptides were identified with
the Flex-Analysis 2.2 software (Bruker), and the Find Pep pro-
gram available on the ExPASy Proteomic Server. Precision for
analysis was set at 0.1%. All the peaks identified as fragments
of rIDEwere distributed in 100-residue segments of the recom-
binant enzyme, and the relative frequency for each segmentwas
expressed as the percentage of the total peaks assigned to rIDE.
RESULTS
IDE and A Form a Complex That Resists Dissociation with
Strong Denaturants—After incubating synthetic A1–40 (25
M) with rat rIDE (1 M), a Western blot with antibody 6E10
specific for A 4–13 showed, in addition to the digestion of the
monomeric peptide, a 120-kDa component consistent with a
complex between the protease (115 kDa) and A (4 kDa).
This high molecular weight component was not present when
A was incubated alone, ruling out an oligomeric form of the
peptide (Fig. 1A). The same results were obtainedwithA1–42
(not shown). No bands in the 120-kDa region were seen when
rIDE was incubated with human CysC (11 kDa). As an addi-
tional negative control ubiquitin was used, which has been
reported to bind and inhibit IDE in a competitive manner (25)
(Fig. 1A). Remarkably, the 120-kDa component resisted disso-
ciation in the presence of 8% SDS, 8 M urea, 70% formic acid, or
6 M guanidine-HCl at pH 3, indicating its extremely high stabil-
ity (Fig. 1B). The shift in mobility of rIDE upon binding to A
was small, consistent with low molecular mass A species as
FIGURE 1. A, incubation of A1– 40 with rIDE results in the formation of an
SDS-resistant component. Left panel: Western blot with 6E10 monoclonal
antibody showing a 120-kDa band after incubation of active rIDE and A
(arrowhead) that is not present when A was incubated alone. Note that
monomeric A was degraded in the presence of rIDE. Middle and right panels,
Western blots (WB) of CysC and ubiquitin incubated alone or in the presence
of rIDE, respectively. CB, Coomassie Blue staining of a gel with the same
amounts of ubiquitin and rIDE as shown in the WB. B, Western blot with 6E10
of A1– 40 alone or preincubated with rIDE after treatment with 8% SDS, 8 M
urea, 70% formic acid, or 6 M guanidine-HCl (G), respectively. C, schematic
representation of A1– 40 and the epitopes recognized by 6E10, 4G8, and S40
antibodies (top panel), and Western blot (bottom panel) with the three anti-
bodies showing the 120-kDa component in the presence of rIDE as indicated
(arrow). BC2 is a polyclonal anti-IDE. On the left, in all panels, molecular mass
markers in kilodaltons. Representative Western blots from at least two inde-
pendent experiments are shown.
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opposed to large SDS-resistant oligomers associated with rIDE.
To explore whether these bound A species were products of
proteolysis, the peptide was incubated with rIDE in the pres-
ence of 5 mM EDTA. The inhibition of proteolytic activity did
not preclude the formation of a stable complex betweenA and
rIDE (IDEASCx). Moreover, monoclonal 4G8 specific for
sequence 17–24 (26) and S40, a polyclonal antibody against the
C-terminal 5 residues of A1–40 (27), showed the same 120-
kDa component aswith 6E10 in the presence of EDTA, suggest-
ing that the species associated with rIDE in IDEASCx was
intact A1–40 rather than fragments of the peptide (Fig. 1C).
To study A-rIDE stable association using an entirely different
approach, A1–40 and rIDE were incubated and subjected to
reversed-phase HPLC. Fractions were analyzed by indirect
ELISA using 6E10, 4G8, S40, and BC2 antibodies to follow the
elution of A and rIDE, respectively. IDE immunoreactivity
wasmainly found in one peak (P2, Fig. 2A), whereas A showed
a biphasic pattern, with most of the peptide eluting at P1 (Fig.
2A) and a second, more hydrophobic and smaller peak that
eluted together with rIDE in P2. A from P2 reacted on ELISA
with 6E10, 4G8, and S40 in accordance with Western blot
results suggesting that a full-length peptide was associated with
rIDE (Fig. 2B). Quantitative estimation by ELISA showed that
15% of A immunoreactivity co-eluted with the protease.
Western blot with 6E10 showed that P1 yieldedmonomeric A
(not shown), whereas P2 contained the SDS-resistant 120-kDa
component (Fig. 2C).
Endogenous IDE andAAreCapable of Forming IDEASCx—
To determine whether endogenous A was capable of forming
IDEASCx, we used purified amyloid from the leptomeninges
of a case of HCHWA-D. These patients present massive vascu-
lar amyloid deposition due to a point mutation in the APP gene
resulting in the substitution of Glu for Gln at position 22 of A
(E22Q). A Dutch was extracted in 99% formic acid and con-
sisted of a mixture of monomers, dimers, and higher oligomers
when analyzed on SDS-PAGE, as previously shown (23). When
endogenous A Dutch was incubated with rIDE, Western blot
revealed a strong 120-kDa band with 6E10 that was not seen in
the absence of rIDE, indicative of IDEASCx (Fig. 3A), and that
the complex formation observed with synthetic peptides was
not an artifact associated with the chemistry of their produc-
tion. Likewise, endogenous IDE isolated from rat brain formed
IDEASCx after incubation with A1–40, indicating that this
stable association was not restricted to the recombinant
enzyme (Fig. 3B). To detect the presence of IDEASCx in vivo,
a detergent-soluble fraction from adult rat brain was immuno-
precipitated with anti-IDE monoclonal 3A2 and analyzed by
Western blot with anti-A S40 and S42. A strong immunore-
active band of 120 kDawas seenwith both a polyclonal anti-IDE
(BC2) and S40 that was absent from the negative controls (Fig.
3C). No S42-reactive band was observed (not shown). To
extend these results to human brain, water-soluble and SDS-
soluble proteins from sporadic AD cortical tissue were immu-
noprecipitated with anti-IDE monoclonal 3A2. Western blot
with anti-A S42, specific for A ending at Ala-42 (27), showed
a component of 120 kDa that was not present in the negative
controls and resisted incubation in 6 M urea (Fig. 3D and sup-
plemental Fig. S2). This band was not detected with S40, possi-
bly due to the overwhelming predominance of A42 over A40
in AD parenchymal deposits (not shown). Remarkably, no
IDEASCx was detected in the water-soluble fractions despite
a larger amount of immunoprecipitated IDE as compared with
the SDS-soluble fraction (supplemental Fig. S2). It is notewor-
thy that S42 yielded exclusively the typical ladder staining of A
oligomers in a direct Western blot of AD brain SDS-soluble
proteins, further indicating its specificity (supplemental Fig.
S2). Although a definite proof will require direct biochemical
characterization after a large scale purification, these results
suggest that IDEASCx exists in vivo in normal rodent brain
and remains associated with amyloid deposits in senile plaques,
in accordance with the reported immunohistochemical find-
ings of IDE in AD brains (28).
The Central Region of A Is Sufficient for IDEA SCx
Formation—Major sites of IDE cleavage and all the A patho-
logic substitutions are clustered within a hydrophobic stretch
FIGURE 2. A, HPLC profile of A1– 40 incubated with rIDE as indicated under
“Material and Methods” showed two major peaks, P1 and P2. B, analysis of the
HPLC fractions by indirect ELISA. rIDE immunoreactivity, as detected with BC2
polyclonal antibody (filled bars) eluted in fractions 13–15, whereas A1– 40
eluted mainly in fraction 11 with a second, minor peak in fraction 14, as
revealed with monoclonal 6E10 (open bars). Data represent the mean  S.E. of
two experiments performed in duplicate. A similar profile was obtained with
antibodies 4G8 and S40 (not shown). C, Western blot of proteins in fractions 13
and 14 showed a 120-kDa component that was labeled by 6E10 in the latter
only (arrow), in agreement with the ELISA results. The left panel shows the
same membrane stripped and blotted with anti-IDE BC2. Note the slight shift
in the molecular mass of the ArIDE complex. Left, molecular mass markers,
in kilodaltons.
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between positions 17 and 24 (reviewed in Ref. 1); in addition,
this region corresponds to the N terminus of p3, a major prod-
uct of APP normal processing by / secretases. We next
probed shorter synthetic A to test the requirement for this
region. The IDEASCx was formed with A1–28 as detected
by 6E10 andwith ACys-16–28 and p3 as shown by 4G8West-
ern blots, respectively (supplemental Fig. S2). Moreover, these
components also resisted treatment with denaturants (not
shown) indicating that the hydrophobic C terminus of the
membrane-embedded domain of A was not necessary for the
strong interaction with rIDE. These results also suggested that
ACys16–28 and p3 in IDEASCx were not cleaved, because
the linear epitope 17–24 recognized by 4G8 was preserved.
Soluble A Is Competent for the Formation of IDEASCx—
We next addressed the question of whether IDEASCx was
formed at the expense of soluble or aggregated A. Preincu-
bated A1–40E22Q remained on top of the gel, indicative of
extensive aggregation and did not show IDEASCx as opposed
to the non-aggregated peptide (Fig. 4A). To more accurately
quantify rIDE-bound A, ACys16–28 was labeled with fluo-
resceinmaleimide (FA), purified by HPLC and characterized
by MALDI-TOF. A single peak with a mass of 1982.5 was
obtained, indicating a 1:1 labeling stoichiometry (not shown).
This allowed an estimation of peptide concentration (which
lacks Tyr and Trp) bymeasuring absorbance at 492 nm at pH 9.
The derivative FAwas used to assess aggregation and complex
formation with rIDE. As with the unlabeled A peptides, SDS-
PAGE showed that FA associated into IDEASCx, whereas
no stable association was seen with bovine serum albumin or
IgG (supplemental Fig. S3). Moreover, FA was competed by
preincubation with a 10-foldmolar excess of unlabeled ACys-
16–28, confirming the specificity of the fluorescent signal (sup-
plemental Fig. S3). Fluorescence intensity in the soluble frac-
tion as a function of concentration and time indicated that FA,
as expected from previous work (29, 30), readily aggregated
above 250 nM after 3 h with continuous agitation at 37 °C (Fig.
4B). The fraction of soluble FA at steady state was20% at 2.5
M. When FA was incubated at 2.5 M with increasing con-
centrations of rIDE (50 nM-2.5 M), the yield of IDEASCx
increased 8-fold up to 500 nM and remained constant to 2.5
M (expressed in monomers of enzyme) (Fig. 4C). A quantita-
tive estimation with dot blots (see supplemental Fig. S3)
showed that the maximal amount of FA associated with rIDE
comprised 16 ng of FA (16% of the total peptide), further
supporting that a species of soluble FA was limiting for
IDEASCx formation under these experimental conditions.
Native IDEASCx Acquires SDS Resistance Very Slowly—
Previous work has shown that native endogenous IDE can be
isolated by size-exclusion chromatography largely as a dimer
(31). Therefore, we subjected rIDE obtained from a Ni2-affin-
ity column to a Superdex-200 separation under physiological
conditions at 1 M and obtained a main peak of apparent
molecular mass of 250 kDa (Fig. 5A). This component was
further characterized by static laser-light scattering as a homo-
geneous 228-kDa species, consistent with a rIDE dimer (not
FIGURE 3. A, Western blot with 6E10 of A from HCHWA-D leptomeninges
incubated in the absence or presence of rIDE. The band of 120 kDa that
reacted with both 6E10 and anti-IDE BC2 is seen. B, Western blot with S40
antibody of IDEASCx formed between A1– 40 and rIDE or endogenous IDE
immunoprecipitated (IPP) from rat brain with anti-IDE monoclonal 3A2. On
top of each lane, the input for IPP is indicated; rIDE, recombinant rat IDE. WB,
Western blot; CB, Coomassie Blue staining of the lower part of the same mem-
brane showing Ig heavy chains. Unr.IgG, unrelated mouse IgG. Note that rIDE
runs slower (8 kDa) on SDS-PAGE than endogenous IDE, as described before
(20). C, top panel, WB with polyclonal anti-IDE BC2 and anti-A S40 of rat brain
proteins after IPP with anti-IDE monoclonal 3A2 shows a specific component
of 120 kDa consistent with endogenous IDEASCx. Unr.IgG, unrelated mouse
IgG. Bottom panel, the lower part of the membrane was stained with Coomas-
sie Blue (CB) to show the Ig heavy chains (Ig) of the immunoprecipitates as
loading controls. D, top panel, Western blot (WB) with S42 of SDS-soluble
proteins form AD cortical tissue after IPP with anti-IDE 3A2 shows a specific
component of 120 kDa consistent with endogenous IDEASCx. Unr.IgG,
unrelated mouse IgG. Bottom panel, the lower part of the membrane was
stained with CB to show the Ig heavy and light chains of the immunoprecipi-
tates as loading controls.
FIGURE 4. A, Western blot of pre-aggregated (Agg.) or soluble (Sol.) A1–
40E22Q in the presence or absence of rIDE, as indicated. The 120-kDa com-
ponent in the presence of rIDE with non-aggregated A is indicated (arrow-
head). B, rate of aggregation of FA in 0.1 M phosphate, pH 7.2, as a function of
peptide concentration. After incubation, FA remaining in the supernatant of
10,000  g was measured at 492 nm at pH 9. 125 nM (), 250 nM (E), 500 nM (),
and 2.5 M (‚). The mean  S.E. of two independent experiments performed
in duplicate for each condition are shown. C, FA at 2.5 M was incubated
with increasing concentrations of rIDE as indicated and IDEASCx detected
and quantitated as described under “Materials and Methods.” There was an
increase of 8-fold in the intensity of the 120-kDa component from 50 to 500
nM of rIDE, where it approached saturation. Left, molecular mass markers in
kilodaltons. Representative gels of two independent experiments are shown.
Insulin-degrading Enzyme and Amyloid  Stable Complex
17044 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283 • NUMBER 25 • JUNE 20, 2008
 by on A









shown). At this rIDE concentration, nomonomerwas detected.
Using [125I]insulin as a substrate,95% of the proteolytic activ-
ity was associated with the dimeric component (Vmax  3.9
fmol/h/g) (not shown) indicating that our active recombinant
protease had a quaternary structure similar to the native mam-
malian enzyme. After incubation with A1–28, Western blot
showed the presence of a 120-kDa band recognized by 4G8 that
co-eluted with the rIDE-containing fractions (Fig. 5A). This
band was not seen when A1–28 was incubated alone (not
shown), indicating that IDEASCx was formed under non-
denaturing conditions, and that native IDEASCx had a simi-
lar molecular mass as rIDE, in accordance with the SDS-PAGE
results described before. Because the hydrophobic region
A29–40 was not necessary for IDEASCx assembly, we used
A1–28 instead of full-length As to follow the time course of
IDEASCx formation. This allowed us to use a high peptide:
enzyme molar ratio to ensure pseudo-first order conditions
while minimizing the rate of A aggregation. Moreover,
MALDI-TOF analysis showed that after incubation with rIDE,
A1–28 was cleaved mainly at His13-His14 and His14-Gln15,
and therefore it was an rIDE substrate with a similar specificity
as A1–40 (12) (supplemental Fig. S4). A1–28 was previously
treated with HFIP, and its aggregation was monitored by
dynamic light scattering. At 100 M, A1–28 remained as a
predominant species of 1 nm, consistent with monomeric
peptide up to 4 h. After 24- and 72-h incubation, large oli-
gomers became evident with apparent hydrodynamic diame-
ters of 300 to 600 nm, respectively (Fig. 5B). A time course of
IDEASCx formation between rIDE and A1–28 under a 100-
fold molar excess of peptide showed that it was a very slow
process that approached steady state at 4 h. Fitting the data to a
single exponential equation yielded an apparent rate constant,
k  0.015 min1 with t1⁄2 of 47.4 min. When rIDE proteolytic
activity was inhibited with EDTA, there was a substantial
increase (10-fold) in the amount of IDEASCx formed yet
with a similar rate (k  0.017 min1) and t1⁄2 (42 min)
(Fig. 5C).
Formation of IDEASCx Is Prevented by Partial Denatur-
ation and Competed by IDE Substrates—We next explored if
soluble A could be binding to rIDE in a substrate-like manner
before IDEASCx was formed. Because binding of A and
other substrates requires a natively folded IDE (14), we first
studied whether rIDE denaturation affected the formation of
IDEASCx. When rIDE was incubated with increasing urea
concentrations, a gradual decrease of molar ellipticity at 222
nm and a red shift of Trp fluorescence were indicative of a loss
of secondary and tertiary structure, respectively, upon denatur-
ation (Fig. 6A). Next, rIDE was incubated with A1–28 under
native conditions or in the presence of increasing concentra-
tions of urea. A substantial reduction of the yield of IDEASCx
was evident between 2 and 3Murea and remained at basal levels
thereafter (Fig. 6A). To extend these results to the shorter
A17–27, FA (supplemental Fig. S3) was incubated with rIDE
with and without prior incubation of the enzyme with 8 M urea.
The yield of IDEASCx under native conditions was 9-fold
higher as compared with denatured rIDE. These results sug-
gested that partially unfolded rIDE was inefficient in forming a
stable complex with A or that the presence of urea prevented
the interaction of A with rIDE (Fig. 6B). To gain information
about the possible binding site on rIDE, competition was per-
formed with insulin, the substrate with the lowest Km for IDE
(32). When insulin was incubated with rIDE at increasing con-
centrations for 1 h before the addition of FA, the yield of
IDEASCx approached a plateau at20% of the initial value in
the absence of insulin (Fig. 6C). The lack of a total displacement
by high concentrations of insulin and the fact that insulin was
ineffective to displace FA when incubated after completion (4
h) of IDEASCx formation (not shown) was indicative of a
population of rIDEA that were not in equilibrium, in accord-
ance with its high resistance to denaturation. Similar results
were obtained when GRF, a known substrate of IDE, was used
(32) (Fig. 6D). These results suggested the interaction of
A17–27 with at least part of a substrate binding site of IDE as
an early step in IDEASCx formation.
Peptides from the Catalytic Domain of IDE Are Tightly Asso-
ciated with A—The previous set of results was consistent with
an encounter complex betweenmonomericA and at least part
of the substrate binding site of IDE followed by a slow transition
leading to IDEASCx. To determine which region of rIDE was
associated with FA in a denaturant-resistant manner,
IDEASCx was subjected to partial proteolysis with trypsin,
separated on SDS-PAGE, and analyzed by protein staining, flu-
orescence, andWestern blot. Coomassie Blue revealed a broad
band of 25-kDa band that was not present in the undigested
sample. Its N-terminal sequence from a PVDF membrane
FIGURE 5. A, separation of IDEASCx under native conditions on a Superdex
200 column. Inset, Western blot with 4G8 of fractions 1 and 2, as indicated.
B, dynamic light scattering of A1–28 pre-treated with HFIP, dissolved in 0.1 M
phosphate, pH 7.2, at 100 M and incubated for the indicated times at 37 °C.
The relative abundance of species and the average hydrodynamic (hyd.)
diameter in Log10 nm are shown for each incubation period. C, time course of
rIDEASCx formation under pseudo-first order conditions assessed by West-
ern blot with 6E10 (inset) without EDTA (left panel) and after Zn2 chelation
with 5 mM EDTA (right panel). Densitometric data from two independent
experiments in duplicate were fit to a single exponential equation. 95% con-
fidence intervals are depicted. Note that both membranes (with or without
EDTA experiments) were developed simultaneously with the STORM 860
scanner.
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yielded 1.5 pmol of a major Ser-Met-Asn-Asn-Pro-Ala-Ile,
starting at the last residue of the pET expression vector. A flu-
orescent and 4G8-immunoreactive band was consistent with
FA bound to this rIDE product (Fig. 7A). To gain more struc-
tural information with a different approach, IDEASCx was
formed with FACys17–27 (which lacks Lys16 and Lys28), the
band of 120 kDa was cut and digested in gel with endo-LysC.
The products were separated by reversed-phase HPLC and
assessed for 4G8 immunoreactivity and fluorescence (Fig. 7B).
Five fractions were analyzed byMALDI-TOF, according to the
presence of both criteria, numbered 36c, 37c, 39c, 40c, and 41c,
respectively. The complete list of endo-LysC fragments that
were assigned to rIDE from these fractions is provided as sup-
plemental material in Table S1. The most frequent IDE pep-
tides recovered from IDEASCx as compared with rIDE alone
were clustered within region 57–131 (supplemental Fig. S5 and
supplemental Table S1). In the absence of an obvious candidate
peptide for anA adduct (not expected to resistMALDI-TOF if
not covalent), a frequency distribution of peptides within 100-
residue segments of IDE was done. A total of 200 peptides that
co-eluted with FA17–27 were assignable to rIDE, of which
15% mapped to the region 51–150 of the protease, a 4-fold
over-representation as compared with the peptides obtained in
the same fractions from rIDE alone (3.5%) (Fig. 7C).
DISCUSSION
Our results indicate that a region of IDE containing the cat-
alytic site is capable of an extremely stable association with A
without prior cleavage of the peptide. Several proteins have
been shown to interact with A in a manner that is resistant to
SDS, including apolipoprotein E isoforms, apolipoprotein J,
2-macroglobulin (2M), transthyretin, gelsolin, and the
7-nicotinic acetylcholine receptor subunit (33–38). Some of
these proteins, like IDE, have been found in close association
with or within amyloid plaques in AD brains (28).4 The best
studied binding requirements were those of the apolipoprotein
EA complex, showing that the N-terminal region of A
His13–Lys16may interact with the C terminus of the peptide for
the strong binding to a natively folded apolipoprotein E (34).
This same region of A has been involved in the binding to
transthyretin, possibly through charge interactions (36). The
shortest A fragment used in this study (positions 17–27) that
was competent to interact with IDE in a stable manner con-
tained the sequence LVFF, known to be important in driving
-sheet formation (30, 39, 40). The A sequence 17–21
(LVFFA) has been shown to form a surface hydrophobic patch
in the metastable “collapsed coil” of A10–35 in water (41),
whereas the A16–28 stretch forms a  strand that may drive
the intermolecular association of fibrillar A (42). Moreover,
the recently resolved three-dimensional structure of an inactive
IDE mutant (E111Q) complexed with several substrate pep-
tides shows that this central stretch (residues 16–23) of A
binds in an extended conformation within the catalytic cleft of
IDE (14). Apart from wild-type A, synthetic and endogenous
A Dutch also bound tightly to IDE, indicating that a negative
charge at residue 22was not necessary for such interaction. The
kinetic of IDEASCx formation under pseudo-first order con-
ditions revealed that it was a very slow process and that its yield
was increased when IDE activity was inhibited by removing
catalytic Zn2 with chelators. Together with the fact that
A1–28 remained largely monomeric throughout the incuba-
tion period, these results suggested three major possibilities: 1)
IDEASCx derived from an encounter complex between sub-
strate and a fully active protease via a pathway that was alterna-
tive to proteolysis, 2) IDEASCxwas generated exclusively by a
population of rIDE molecules with a very slow kcat or with no
catalytic activity (i.e. due to conformational changes or the
absence of Zn2), and 3) A occupied a region in IDE that
overlapped only partially with the canonic binding site and
therefore catalytically inactive. The study of the kinetic of inhi-
bition using very sensitive IDE substrates comparing free IDE
and IDEASCx will help to decide between these alternatives
and allow a more in-depth mechanistic interpretation. Our
results indicate that monomeric or very low order oligomers of
A and anatively folded IDEwere the competent species for the
assembly of IDEASCx. IDEASCx was strongly competed
out when IDE was preincubated with two good IDE substrates
such as insulin and GRF. The facts that competition was not
4 V. Dorfman and L. Morelli, unpublished observations.
FIGURE 6. A, chemical denaturation of rIDE, as assessed by Trp fluorescence
center of spectral mass () and loss of molar ellipticity at 222 nm (Œ). rIDE was
incubated in 50 mM phosphate buffer, pH 7.2, at room temperature in the
presence of the indicated concentrations of urea for 1 h and then incubated
with A1–28 for 3 h at 37 °C. Inset: Western blot with 6E10 of IDEASCx at the
indicated urea concentrations. B, effect of 8 M urea upon the yield of FA-rIDE
SDS-resistant complex applied to rIDE before incubation with the peptide
(urea  FA) or after the complex was formed (FA  urea). Fluorescence scan
(top) and Coomassie Blue staining of the same membrane (bottom) to show
rIDE amounts. C, IDEASCx was competed when the enzyme was preincu-
bated for 1 h with increasing concentrations of insulin. Data were plotted as
the percentage of remaining 120-kDa complex as a function of insulin:FA
molar ratio. Points represent the mean  S.E. of three independent experi-
ments. Inset: fluorescence detection of bound FA. D, fluorescence detection
of FA after SDS-PAGE shows that incubation of rIDE with an excess of GRF for
1 h before the addition of FA prevents IDEASCx formation (GRF  A).
There is no displacement of FA after IDEASCx was formed (A  GRF).
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complete and that there was no displacement of A when
IDEASCxwas allowed to formbefore the addition of compet-
itor were concurrent with a non-equilibrium reaction between
A and rIDE. Our limited proteolysis and mass spectrometry
findings fully agreed with the competition experiments, show-
ing that IDE peptides within the catalytic domain were prefer-
entially retrieved after HPLC in tight association with A17–
27. Collectively, these results suggest that monomeric A
interacts with part of the substrate-binding site of IDE to yield,
via a slow rearrangement, the irreversible peptideprotease
complex. Kurochkin (11) has proposed that the substrate spec-
ificity of IDE is realized at the binding stage, a step in which the
protease “senses” the potential of the peptide to adopt an
extended  conformation by providing a template that pro-
motes this conversion. The spatial distribution of insulin B
chain, amylin, glucagon, and A1–40 associated with an inac-
tive mutant of IDE fully supports such mechanism (14). Self-
assembly of amyloidogenic peptides usually results in very sta-
ble end products that can resist harsh chemical denaturation.
As a remarkable example in vivo, soluble neurotoxic A oli-
gomers of 56 kDa found in the brains of APP transgenic mice,
completely resisted denaturation
with 8 M urea, whereas smaller A
oligomers resisted treatment with
HFIP (43). The extended conforma-
tion of A16–23 in its IDE-bound
form (14) and the biochemical data
presented here raise the intriguing
possibility that the tight association
between IDE and A, despite being
heterologous, may share thermody-
namic and structural features with
the self-assembly of amyloid pep-
tides. In vitro seeding experiments
of amylin with A fibrils partially
support this possibility (44). The
occurrence of a covalent binding
between rIDE and A cannot be
excluded completely, yet, there are
no covalent intermediates of amide
hydrolysis by metallopeptidases as
opposed to serine or cysteine pro-
teases (45) and the removal of cata-
lytic Zn2 greatly enhanced
IDEASCx formation, pointing to a
non-catalytic-dependent mecha-
nism. The high conservation of IDE,
together with the convergent evolu-
tion of the catalytic fold of Zn2-
metallopeptidases such as thermo-
lysin and neprilysin, suggests that a
common strategy has prevailed for
the degradation of peptides prone to
adopt an extended conformation
(46, 47). IDE, in addition to its func-
tion as an insulin peptidase, may act
in cellular and extracellular com-
partments as a scavenger of pep-
tides with a high propensity to form  aggregates by degrading
them at a monomeric stage. Nonetheless, the present results
tempt us to speculate that an irreversible, non-catalytic binding
may represent an alternative to trapmetastable peptides before
they reach a critical concentration that would promote nucle-
ation and render them less accessible to proteolysis in vivo. It
remains as a testable prediction for further investigation
whether IDE is capable of forming stable complexes with other
amyloidogenic peptides besides A. This type of interaction
may be a general property of IDE and may acquire pathogenic
importance in the context of tissue specificity of amyloid accu-
mulation. In the case of the AD brain, a stoichiometric irrevers-
ible complex involving A and a “suicide” conformer of IDE
that enters a dead-end pathway may compromise insulin turn-
over and promote local insulin resistance under conditions in
which A is produced at a high rate such as during cellular
hypoxic stress (48). Moreover, the sensitivity of IDE to oxida-
tive damage (21, 22)may reduce its catalytic activity and further
promote the formation of IDEASCx. In the case of A1–40,
the apparent Km for IDE is 0.8–2 M (18, 49) and the reported
critical concentration varies from 1 to 20 M (50, 51) thus
FIGURE 7. A, top panel, Coomassie blue (CB) staining, fluorescence, and Western blot with 4G8 of rIDE after
incubation with FA, undigested and partially digested with trypsin, as indicated. The arrow shows FA bound
to a 25-kDa tryptic rIDE fragment. Bottom panel, schematic representation of the N-terminal domain of rat IDE
(IDE N-t) showing the N-terminal sequence obtained from the 25-kDa tryptic fragment. Residues involved in
catalysis are depicted in italics. Numbering follows the full-length cDNA of rat IDE. B, top panel, HPLC profiles of
the in-gel endo-LysC digestion of rIDE alone or preincubated with FA17–27. Bottom panel, fluorescence and
A immunoreactivity of the HPLC fractions after in gel digestion of IDEASCx. Bars represent the mean  S.E.
of duplicates from two independent experiments. C, frequency distribution of all the endo-LysC peptides
derived from fractions 36, 37, 39, 40, and 41 that were assigned to rIDE sequence from two independent
experiments performed in duplicate. Open bars, rIDE alone; filled bars, rIDE incubated with FA17–27. The
asterisk indicates the 4-fold over-representation of peptides from the region 51–150 of rIDE. Note that the
numbering refers to our recombinant IDE and that the N-terminal 49 residues are from the pET sequence.
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making the system highly sensitive to A overproduction
and/or accumulation with regard to the degradation-aggrega-
tion balance. This may also be relevant to the most abundant
product of APP processing by / secretases, the p3 peptides
that contain the sequence 17–27 of A and are amajor compo-
nent of diffuse plaques in AD (52, 53). In summary, our results
raise the possibility of a novel conformation-dependent inter-
action between IDE and A peptide substrates with potential
pathogenic implications in sporadic AD and related disorders.
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